Mometasone Furoate

DRUG INFORMATION

  ADULT
    - In patients with a known seasonal allergen that precipitates nasal symptoms of
      seasonal allergic rhinitis, prophylaxis with 2 sprays (2 sprays deliver a total of
      100 mcg of mometasone furoate) in each nostril once daily (total daily dose of 200
      mcg) is recommended 2 to 4 weeks prior to the anticipated start of the pollen
      season.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section 'dosage
      and administration', retrieved 2026-08-29
    - A dose of 2 sprays (2 sprays deliver a total of 100 mcg of mometasone furoate) in
      each nostril once daily (total daily dose of 200 mcg) is also effective in some
      patients.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section 'dosage
      and administration', retrieved 2026-08-29
    - For Nasal Use Only Prophylaxis of Seasonal Allergic Rhinitis in Adult and
      Pediatric Patients 12 Years of Age and Older: 2 sprays in each nostril once daily
      ( 2.2 ) Treatment of Chronic Rhinosinusitis with Nasal Polyps in Adults (18 yrs.
      and older): 2 sprays in each nostril twice daily.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section 'dosage
      and administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of mometasone furoate nasal spray for prophylaxis of
      the nasal symptoms of seasonal allergic rhinitis in pediatric patients 12 years of
      age and older have been established [see Adverse Reactions ( 6.1 ) and Clinical
      Studies ( 14.1 )]. Use of mometasone furoate nasal spray forthis indication is
      supported by evidence from controlled trials in adult and pediatric patients 12
      years of age and older [see Clinical Studies ( 14.1 )].
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section
      'pediatric use', retrieved 2026-08-29
    - For Nasal Use Only Prophylaxis of Seasonal Allergic Rhinitis in Adult and
      Pediatric Patients 12 Years of Age and Older: 2 sprays in each nostril once daily
      ( 2.2 ) Treatment of Chronic Rhinosinusitis with Nasal Polyps in Adults (18 yrs.
      and older): 2 sprays in each nostril twice daily.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section 'dosage
      and administration', retrieved 2026-08-29
    - A total of 127 patients with chronic rhinosinusitis with nasal polyps were
      randomized to placebo or mometasone furoate nasal spray 100 mcg once or twice
      daily (patients 6 to 11 years of age) or 200 mcg once or twice daily (patients 12
      to 17 years of age).
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section
      'pediatric use', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for mometasone furoate (MOMETASONE
      FUROATE), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No observed differences in safety and/or effectiveness in geriatric patients
      compared to younger adult patients. 8.6 Hepatic Impairment Concentrations of
      mometasone furoate appear to increase with severity of hepatic impairment [see
      Clinical Pharmacology (12.3) ] .
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section 'use in
      specific populations', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Mometasone is minimally absorbed systemically following nasal use,
      and maternal use is not expected to result in fetal exposure to the drug.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section
      'pregnancy', retrieved 2026-08-29
    - Available data from observational studies of mometasone use in pregnant women are
      insufficient to evaluate for a drug-associated risk of major birth defects,
      miscarriage or other adverse maternal or fetal outcomes.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section
      'pregnancy', retrieved 2026-08-29
    - In animal reproduction studies with pregnant mice, rats, or rabbits (subcutaneous,
      subcutaneous/topical dermal/oral, and topical dermal/oral, respectively),
      mometasone furoate caused increased fetal malformations and decreased fetal
      survival and growth following administration of doses that produced exposures
      approximately 1/3 to 8 times the maximum recommended human dose (MRHD) on a mcg/m
      2 or AUC basis [see Data].
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - Risk Summary There are no available data on the presence of mometasone furoate
      nasal spray in human milk, the effects on the breastfed child, or the effects on
      milk production.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section 'nursing
      mothers', retrieved 2026-08-29
    - However, mometasone is minimally absorbed systemically by the mother following
      nasal use, and breastfeeding is not expected to result in exposure of the infant
      to mometasone.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section 'nursing
      mothers', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for mometasone furoate nasal spray and any
      potential adverse effects on the breastfed infant from mometasone furoate nasal
      spray or from the underlying maternal condition.
      Source: US FDA label for mometasone furoate (MOMETASONE FUROATE), section 'nursing
      mothers', retrieved 2026-08-29